Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort

Paola A. Zeña-Huancas, Haydee Iparraguirre-López, Rocío V. Gamboa-Cárdenas, Cristina Reátegui-Sokolova, Francisco Zevallos-Miranda, Mariela Medina-Chinchon, Victor R. Pimentel-Quiroz, Claudia Elera-Fitzcarrald, Omar Sarmiento-Velasquez, Jorge M. Cucho-Venegas, José L. Alfaro-Lozano, Zoila J. Rodríguez-Bellido, César A. Pastor-Asurza, Risto A. Perich-Campos, Graciela S. Alarcón, Manuel F. Ugarte-Gil

Resultado de la investigación: Contribución a una revistaArtículoInvestigaciónrevisión exhaustiva

Resumen

© 2018, International League of Associations for Rheumatology (ILAR). Objective: To determine the impact of homocysteine levels on damage accrual in systemic lupus erythematosus (SLE) patients. Methods: This longitudinal study was conducted in consecutive patients seen every 6 months at our Rheumatology Department since 2012. Patients with available homocysteine levels and who had at least one subsequent visit were included. Univariable and multivariable Cox regression models were done to determine if homocysteine levels were predictive of damage accrual as per the SLICC Damage Index (SDI). The multivariable model was adjusted for pertinent variables (age at diagnosis, gender, socioeconomic status, disease duration, disease activity (SLEDAI), Framingham score, antimalarial and immunosuppressive drug use, average daily dose, and exposure time to prednisone (PDN)). Results: One hundred forty-five patients were included; their mean (SD) age at diagnosis was 43.70 (12.09) years, 136 (93.8%) were female, and nearly all were Mestizo. At baseline, disease duration was 7.55 (6.73) years; patients were followed for 3.54 (1.27) years. The SLEDAI was 5.60 (4.34), and the SDI 0.97 (1.35). The average daily PDN dose was 7.30 (5.78) mg/day and the time of PDN exposure was 7.36 (6.73) years. Mean homocysteine levels were 10.07 (3.71) μmol/L. The highest tertile of homocysteine levels predicted new damage accrual in the univariable and multivariable models [HR 1.78 (95% CI, 1.042–3.039); p = 0.035 and HR 2.045 (95% CI, 1.077–3.883); p = 0.029, respectively]. Increased levels (> 15 μmol/L) were found in 12 (8.3%) patients; 75 (51.7%) patients increased ≥ 1 SDI point. Conclusion: In SLE patients, homocysteine levels predicted damage accrual independently of other well-known risk factors for such occurrence.
Idioma originalInglés estadounidense
Páginas (desde-hasta)1139-1146
Número de páginas8
PublicaciónClinical Rheumatology
DOI
EstadoPublicada - 2 abr 2019

Huella dactilar

Homocysteine
Systemic Lupus Erythematosus
Prednisone
Rheumatology
Antimalarials
Immunosuppressive Agents
Proportional Hazards Models
Social Class
Longitudinal Studies

Citar esto

Zeña-Huancas, P. A., Iparraguirre-López, H., Gamboa-Cárdenas, R. V., Reátegui-Sokolova, C., Zevallos-Miranda, F., Medina-Chinchon, M., ... Ugarte-Gil, M. F. (2019). Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort. Clinical Rheumatology, 1139-1146. https://doi.org/10.1007/s10067-018-4389-3
Zeña-Huancas, Paola A. ; Iparraguirre-López, Haydee ; Gamboa-Cárdenas, Rocío V. ; Reátegui-Sokolova, Cristina ; Zevallos-Miranda, Francisco ; Medina-Chinchon, Mariela ; Pimentel-Quiroz, Victor R. ; Elera-Fitzcarrald, Claudia ; Sarmiento-Velasquez, Omar ; Cucho-Venegas, Jorge M. ; Alfaro-Lozano, José L. ; Rodríguez-Bellido, Zoila J. ; Pastor-Asurza, César A. ; Perich-Campos, Risto A. ; Alarcón, Graciela S. ; Ugarte-Gil, Manuel F. / Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort. En: Clinical Rheumatology. 2019 ; pp. 1139-1146.
@article{1b164a7f18fb405f9d39d364e1179c13,
title = "Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort",
abstract = "{\circledC} 2018, International League of Associations for Rheumatology (ILAR). Objective: To determine the impact of homocysteine levels on damage accrual in systemic lupus erythematosus (SLE) patients. Methods: This longitudinal study was conducted in consecutive patients seen every 6 months at our Rheumatology Department since 2012. Patients with available homocysteine levels and who had at least one subsequent visit were included. Univariable and multivariable Cox regression models were done to determine if homocysteine levels were predictive of damage accrual as per the SLICC Damage Index (SDI). The multivariable model was adjusted for pertinent variables (age at diagnosis, gender, socioeconomic status, disease duration, disease activity (SLEDAI), Framingham score, antimalarial and immunosuppressive drug use, average daily dose, and exposure time to prednisone (PDN)). Results: One hundred forty-five patients were included; their mean (SD) age at diagnosis was 43.70 (12.09) years, 136 (93.8{\%}) were female, and nearly all were Mestizo. At baseline, disease duration was 7.55 (6.73) years; patients were followed for 3.54 (1.27) years. The SLEDAI was 5.60 (4.34), and the SDI 0.97 (1.35). The average daily PDN dose was 7.30 (5.78) mg/day and the time of PDN exposure was 7.36 (6.73) years. Mean homocysteine levels were 10.07 (3.71) μmol/L. The highest tertile of homocysteine levels predicted new damage accrual in the univariable and multivariable models [HR 1.78 (95{\%} CI, 1.042–3.039); p = 0.035 and HR 2.045 (95{\%} CI, 1.077–3.883); p = 0.029, respectively]. Increased levels (> 15 μmol/L) were found in 12 (8.3{\%}) patients; 75 (51.7{\%}) patients increased ≥ 1 SDI point. Conclusion: In SLE patients, homocysteine levels predicted damage accrual independently of other well-known risk factors for such occurrence.",
author = "Ze{\~n}a-Huancas, {Paola A.} and Haydee Iparraguirre-L{\'o}pez and Gamboa-C{\'a}rdenas, {Roc{\'i}o V.} and Cristina Re{\'a}tegui-Sokolova and Francisco Zevallos-Miranda and Mariela Medina-Chinchon and Pimentel-Quiroz, {Victor R.} and Claudia Elera-Fitzcarrald and Omar Sarmiento-Velasquez and Cucho-Venegas, {Jorge M.} and Alfaro-Lozano, {Jos{\'e} L.} and Rodr{\'i}guez-Bellido, {Zoila J.} and Pastor-Asurza, {C{\'e}sar A.} and Perich-Campos, {Risto A.} and Alarc{\'o}n, {Graciela S.} and Ugarte-Gil, {Manuel F.}",
year = "2019",
month = "4",
day = "2",
doi = "10.1007/s10067-018-4389-3",
language = "American English",
pages = "1139--1146",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer Verlag",

}

Zeña-Huancas, PA, Iparraguirre-López, H, Gamboa-Cárdenas, RV, Reátegui-Sokolova, C, Zevallos-Miranda, F, Medina-Chinchon, M, Pimentel-Quiroz, VR, Elera-Fitzcarrald, C, Sarmiento-Velasquez, O, Cucho-Venegas, JM, Alfaro-Lozano, JL, Rodríguez-Bellido, ZJ, Pastor-Asurza, CA, Perich-Campos, RA, Alarcón, GS & Ugarte-Gil, MF 2019, 'Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort', Clinical Rheumatology, pp. 1139-1146. https://doi.org/10.1007/s10067-018-4389-3

Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort. / Zeña-Huancas, Paola A.; Iparraguirre-López, Haydee; Gamboa-Cárdenas, Rocío V.; Reátegui-Sokolova, Cristina; Zevallos-Miranda, Francisco; Medina-Chinchon, Mariela; Pimentel-Quiroz, Victor R.; Elera-Fitzcarrald, Claudia; Sarmiento-Velasquez, Omar; Cucho-Venegas, Jorge M.; Alfaro-Lozano, José L.; Rodríguez-Bellido, Zoila J.; Pastor-Asurza, César A.; Perich-Campos, Risto A.; Alarcón, Graciela S.; Ugarte-Gil, Manuel F.

En: Clinical Rheumatology, 02.04.2019, p. 1139-1146.

Resultado de la investigación: Contribución a una revistaArtículoInvestigaciónrevisión exhaustiva

TY - JOUR

T1 - Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort

AU - Zeña-Huancas, Paola A.

AU - Iparraguirre-López, Haydee

AU - Gamboa-Cárdenas, Rocío V.

AU - Reátegui-Sokolova, Cristina

AU - Zevallos-Miranda, Francisco

AU - Medina-Chinchon, Mariela

AU - Pimentel-Quiroz, Victor R.

AU - Elera-Fitzcarrald, Claudia

AU - Sarmiento-Velasquez, Omar

AU - Cucho-Venegas, Jorge M.

AU - Alfaro-Lozano, José L.

AU - Rodríguez-Bellido, Zoila J.

AU - Pastor-Asurza, César A.

AU - Perich-Campos, Risto A.

AU - Alarcón, Graciela S.

AU - Ugarte-Gil, Manuel F.

PY - 2019/4/2

Y1 - 2019/4/2

N2 - © 2018, International League of Associations for Rheumatology (ILAR). Objective: To determine the impact of homocysteine levels on damage accrual in systemic lupus erythematosus (SLE) patients. Methods: This longitudinal study was conducted in consecutive patients seen every 6 months at our Rheumatology Department since 2012. Patients with available homocysteine levels and who had at least one subsequent visit were included. Univariable and multivariable Cox regression models were done to determine if homocysteine levels were predictive of damage accrual as per the SLICC Damage Index (SDI). The multivariable model was adjusted for pertinent variables (age at diagnosis, gender, socioeconomic status, disease duration, disease activity (SLEDAI), Framingham score, antimalarial and immunosuppressive drug use, average daily dose, and exposure time to prednisone (PDN)). Results: One hundred forty-five patients were included; their mean (SD) age at diagnosis was 43.70 (12.09) years, 136 (93.8%) were female, and nearly all were Mestizo. At baseline, disease duration was 7.55 (6.73) years; patients were followed for 3.54 (1.27) years. The SLEDAI was 5.60 (4.34), and the SDI 0.97 (1.35). The average daily PDN dose was 7.30 (5.78) mg/day and the time of PDN exposure was 7.36 (6.73) years. Mean homocysteine levels were 10.07 (3.71) μmol/L. The highest tertile of homocysteine levels predicted new damage accrual in the univariable and multivariable models [HR 1.78 (95% CI, 1.042–3.039); p = 0.035 and HR 2.045 (95% CI, 1.077–3.883); p = 0.029, respectively]. Increased levels (> 15 μmol/L) were found in 12 (8.3%) patients; 75 (51.7%) patients increased ≥ 1 SDI point. Conclusion: In SLE patients, homocysteine levels predicted damage accrual independently of other well-known risk factors for such occurrence.

AB - © 2018, International League of Associations for Rheumatology (ILAR). Objective: To determine the impact of homocysteine levels on damage accrual in systemic lupus erythematosus (SLE) patients. Methods: This longitudinal study was conducted in consecutive patients seen every 6 months at our Rheumatology Department since 2012. Patients with available homocysteine levels and who had at least one subsequent visit were included. Univariable and multivariable Cox regression models were done to determine if homocysteine levels were predictive of damage accrual as per the SLICC Damage Index (SDI). The multivariable model was adjusted for pertinent variables (age at diagnosis, gender, socioeconomic status, disease duration, disease activity (SLEDAI), Framingham score, antimalarial and immunosuppressive drug use, average daily dose, and exposure time to prednisone (PDN)). Results: One hundred forty-five patients were included; their mean (SD) age at diagnosis was 43.70 (12.09) years, 136 (93.8%) were female, and nearly all were Mestizo. At baseline, disease duration was 7.55 (6.73) years; patients were followed for 3.54 (1.27) years. The SLEDAI was 5.60 (4.34), and the SDI 0.97 (1.35). The average daily PDN dose was 7.30 (5.78) mg/day and the time of PDN exposure was 7.36 (6.73) years. Mean homocysteine levels were 10.07 (3.71) μmol/L. The highest tertile of homocysteine levels predicted new damage accrual in the univariable and multivariable models [HR 1.78 (95% CI, 1.042–3.039); p = 0.035 and HR 2.045 (95% CI, 1.077–3.883); p = 0.029, respectively]. Increased levels (> 15 μmol/L) were found in 12 (8.3%) patients; 75 (51.7%) patients increased ≥ 1 SDI point. Conclusion: In SLE patients, homocysteine levels predicted damage accrual independently of other well-known risk factors for such occurrence.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85058298068&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85058298068&origin=inward

U2 - 10.1007/s10067-018-4389-3

DO - 10.1007/s10067-018-4389-3

M3 - Article

SP - 1139

EP - 1146

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

ER -